Drugs / Varicella Virus Vaccine Live (Oka-Merck)
Varicella Virus Vaccine Live (Oka-Merck)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00496327 | Jun → Oct 2005 | chickenpox | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-03-06 | Merck Sharp & Dohme LLC | Regulatory US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live) merck.com ↗
In the U.S., the only measles, mumps, rubella, and varicella vaccines that can be administered IM are M-M-R ® II , VARIVAX ® , and ProQuad ® . |
| 2018-02-09 | Merck Sharp & Dohme LLC | Regulatory VARIVAX, Merck’s Varicella (Chickenpox) Vaccine, Awarded WHO Pre-Qualification Status merck.com ↗
VARIVAX, which has been part of the Pan American Health Organization (PAHO) vaccine portfolio for several years and is used in many national vaccination programs, is the first varicella vaccine to receive WHO prequalification. |
| 2013-10-28 | Merck Sharp & Dohme LLC | Regulatory Merck Announces Third-Quarter 2013 Financial Results merck.com ↗
Received approval from the FDA to manufacture bulk varicella |
| 2013-09-04 | Merck Sharp & Dohme LLC | Regulatory Merck’s Durham Site Receives U.S. FDA Licensure for Varicella Bulk merck.com ↗
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture bulk varicella at the company’s site in Durham, N.C. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-03-06 | Merck Sharp & Dohme LLC | US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live) merck.com ↗ |
| 2018-02-09 | Merck Sharp & Dohme LLC | VARIVAX, Merck’s Varicella (Chickenpox) Vaccine, Awarded WHO Pre-Qualification Status merck.com ↗ |
| 2013-10-28 | Merck Sharp & Dohme LLC | Merck Announces Third-Quarter 2013 Financial Results merck.com ↗ |
| 2013-09-04 | Merck Sharp & Dohme LLC | Merck’s Durham Site Receives U.S. FDA Licensure for Varicella Bulk merck.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Varicella Virus Vaccine Live (Oka/Merck) | “VARIVAX(TM) (Refrigerated) \[Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.\] Subjects enrolled in the study received one 0.5 mL subcutaneous dose...” NCT00496327 ↗ |
| Known as | VARIVAX(TM) | “VARIVAX(TM) (Refrigerated) \[Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.\] Subjects enrolled in the study received one 0.5 mL subcutaneous dose...” NCT00496327 ↗ |
| Known as | VARIVAX(TM) (Refrigerated) | “VARIVAX(TM) (Refrigerated) \[Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.\] Subjects enrolled in the study received one 0.5 mL subcutaneous dose...” NCT00496327 ↗ |
| Modality | Vaccine | “Varicella Virus Vaccine Live (Oka-Merck)” NCT00496327 ↗ |
| Route | Subcutaneous | “one 0.5 mL subcutaneous dose of VARIVAX(TM)” NCT00496327 ↗ |